S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Lixte Biotechnology Stock Forecast, Price & News

+0.06 (+3.31 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume47,328 shs
Average Volume531,542 shs
Market Capitalization$25.71 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LIXT News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Lixte Biotechnology logo

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company, that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The firm focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.12 per share





Market Cap
$25.71 million
Next Earnings Date
11/9/2021 (Estimated)
Not Optionable


Overall MarketRank

0.33 out of 5 stars

Medical Sector

1312th out of 1,361 stocks

Pharmaceutical Preparations Industry

642nd out of 668 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Lixte Biotechnology (NASDAQ:LIXT) Frequently Asked Questions

What stocks does MarketBeat like better than Lixte Biotechnology?

Wall Street analysts have given Lixte Biotechnology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lixte Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lixte Biotechnology?

Lixte Biotechnology saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 48,400 shares, an increase of 25.4% from the September 15th total of 38,600 shares. Based on an average trading volume of 382,200 shares, the short-interest ratio is currently 0.1 days. Approximately 0.9% of the company's stock are short sold.
View Lixte Biotechnology's Short Interest

When is Lixte Biotechnology's next earnings date?

Lixte Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Lixte Biotechnology

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) released its earnings results on Tuesday, August, 10th. The company reported ($0.13) earnings per share for the quarter.
View Lixte Biotechnology's earnings history

How has Lixte Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Lixte Biotechnology's stock was trading at $0.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LIXT stock has increased by 110.1% and is now trading at $1.87.
View which stocks have been most impacted by COVID-19

Who are Lixte Biotechnology's key executives?

Lixte Biotechnology's management team includes the following people:
  • John S. Kovach, Chairman, President & Chief Executive Officer
  • Robert N. Weingarten, Chief Financial Officer & Vice President
  • James S. Miser, Chief Medical Officer
  • Eric J. Forman, Chief Administrative Officer

When did Lixte Biotechnology IPO?

(LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital acted as the underwriters for the IPO.

What is Lixte Biotechnology's stock symbol?

Lixte Biotechnology trades on the NASDAQ under the ticker symbol "LIXT."

How do I buy shares of Lixte Biotechnology?

Shares of LIXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lixte Biotechnology's stock price today?

One share of LIXT stock can currently be purchased for approximately $1.87.

How much money does Lixte Biotechnology make?

Lixte Biotechnology has a market capitalization of $25.71 million.

How many employees does Lixte Biotechnology have?

Lixte Biotechnology employs 4 workers across the globe.

What is Lixte Biotechnology's official website?

The official website for Lixte Biotechnology is www.lixte.com.

Where are Lixte Biotechnology's headquarters?

Lixte Biotechnology is headquartered at 248 ROUTE 25A NO. 2, EAST SETAUKET NY, 11733.

How can I contact Lixte Biotechnology?

Lixte Biotechnology's mailing address is 248 ROUTE 25A NO. 2, EAST SETAUKET NY, 11733. The company can be reached via phone at (631) 830-7092 or via email at [email protected].

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.